The core activity of Noema Pharma is the development and marketing of therapeutics for central nervous system (CNS) disorders. The company focuses on developing treatments for rare and severe brain and nervous system diseases, such as Tuberous Sclerosis, Trigeminal Neuralgia, Tourette's Syndrome, and Menopause symptoms.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Late-stage development of oral small-molecule therapeutics with well-characterised mechanisms of action for neurological and related diseases.
Clinical programs for trigeminal neuralgia
Clinical development programme for the treatment of pain in trigeminal neuralgia with Basimglurant (NOE-101), Phase 2/3.
Clinical programs for vasomotor symptoms of menopause
Clinical development programme for non-hormonal treatment of vasomotor symptoms of menopause, including hot flushes and night sweats, with Cendifensine (NOE-115).
Educational materials on neurological diseases and menopause symptoms
Information and resource offerings on trigeminal neuralgia and menopause-related vasomotor symptoms for patients, families, caregivers and professionals.
Partnerships and investor relations
Strategic collaborations and investments to develop treatments for rare and often overlooked diseases of the nervous system.
Knowledge
No knowledge articles yet
Once Noema Pharma AG has claimed this profile, we'll publish editorial articles and case studies here together.